Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 18/20 | 0.84 |
| ▸ | CSF1R | P07333 | 17/20 | 0.84 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.84 |
| ▸ | KIT | P10721 | 4/20 | 0.84 |
| ▸ | PDGFRA | P16234 | 4/20 | 0.84 |
| ▸ | RET | P07949 | 1/20 | 0.47 |
| ▸ | RAF1 | P04049 | 2/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1698732 | 0.97 | FLT3 (0.79) | FLT3CSF1RPDGFRBKITPDGFRA | |
| SCHEMBL1698701 | 0.91 | FLT3 (1.00) | FLT3CSF1RPDGFRBKITPDGFRA | |
| SCHEMBL9980593 | 0.91 | CSF1R (0.70) | FLT3CSF1RPDGFRBKITPDGFRA | |
| SCHEMBL1698727 | 0.90 | CSF1R (0.85) | FLT3CSF1RPDGFRBKITPDGFRA | |
| SCHEMBL20484791 | 0.88 | FLT3 (0.94) | FLT3CSF1RPDGFRBKITPDGFRA | |
| SCHEMBL1698796 | 0.88 | FLT3 (0.94) | FLT3CSF1RPDGFRBKITPDGFRA | |
| SCHEMBL1698692 | 0.88 | FLT3 (0.75) | FLT3CSF1RPDGFRBKITPDGFRA | |
| SCHEMBL1698939 | 0.87 | CSF1R (0.80) | FLT3CSF1RPDGFRBKITPDGFRA | |
| SCHEMBL1698753 | 0.86 | FLT3 (1.00) | FLT3CSF1RPDGFRBKITPDGFRA | |
| SCHEMBL1698773 | 0.85 | FLT3 (0.87) | FLT3CSF1RPDGFRBKITPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9296722-B2 | Azolyl urea compounds and methods of use thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2016-03-29 | — | — | US | disclosed |
| US-9296722-B2 | Azolyl urea compounds and methods of use thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2016-03-29 | — | — | US | disclosed |
| US-20130310357-A1 | Azolyl Urea Compounds and Methods of Use Thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2013-11-21 | — | — | US | disclosed |
| WO-2011150198-A1 | AZOLYL UREA COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2011-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130310357-A1 | Azolyl Urea Compounds and Methods of Use Thereof | CSF1R, CSF3R, ARG1 | FLT3 4/4885CSF1R 1/4885PDGFRB 733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.